Proceedings of the NATIONAL ACADEMY of SCIENCES

Total Page:16

File Type:pdf, Size:1020Kb

Proceedings of the NATIONAL ACADEMY of SCIENCES Proceedings of the NATIONAL ACADEMY OF SCIENCES Volume 40 . Number 9 . September 15, 1954 GLUCOSAMINE KINASE OF SCHISTOSOMA MANSONI* BY ERNEST BUEDINGt HOWARD RUPPENDERf AND JOAN MACKINNON DEPARTMENT OF PHARMACOLOGY, WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE, CLEVELAND, OHIO Communicated by Harland G. Wood, May 28, 1964 The parasitic trematode Schistosoma marsoni is dependent for survival on ana- erobic glycolysis which occurs at an extremely rapid rate.1 As in mammalian- tis- sues, formation of lactic acid by homogenates and extracts of the worms proceeds via the Embden-Meyerhof scheme.2 Opportunities for inhibiting glycolysis of schistosomes without injury to the host would be available if the-glycolytic enzymes catalyzing the same reactions in the parasite and in mammalian tissues were not identical. The existence of such differences has been observed recently. For example, the functional integrity of phosphohexose isomerase of Schistosoma man- soni is inhibited by an antibody which does not affect the activity of the isomerase of rabbit muscle.3 The lactic dehydrogenases of schistosomes and of rabbit muscle can be distinguished from each other not only by their behavior toward specific antibodies4 but also by their affinity to one of their substrates (pyruvate) and by the effect of pH on their activities.5 Furthermore, comparison of the properties of the hexokinases of the parasite with those of the host have revealed differences in the kinetics as well as in substrate specificities.' 6 Sols and Crane7 have demon- strated that purified brain hexokinase catalyzes the phosphorylation of glucose, of fructose, of mannose, of glucosamine, and of other hexoses by adenosine triphos- phate (ATP). The same is true for crystallized yeast hexokinase.8' 9 On the other hand, Schistosoma mansoni contains three distinct hexokinases,3' 6 each one of which reacts specifically with only one hexose, either glucose, fructose, or mannose. None of these three kinases reacts with glucosamine.2 In the present communication it is reported that the worms contain a fourth hexokinase which catalyzes the Phos- phorylation of glucosamine by ATP. On the basis of these differences in the nature of the hexokinases of schistosomes from those of the host, the effect of glucosamine on the parasite was tested, and it was observed that this hexose is active against Schistosoma mansoni in vitro and in vivo. Glucosamine kinase and glucokinase activities were measured by incubating the enzyme preparation of the worms with the hexose and with ATP for a period of 10 minutes at 370 C. The final molar concentrations of the constituents in the reaction mixture were as follows: glucosamine (or glucose), 1.5 X 10-3; ATP, 7 X 10-3; MgCl2, 1 X 10-2; potassium glycylglycine buffer (pH 7.1 for the deter- mination of glucosamine kinase and 7.5 for that of glucokinase activity), 5 X 10-2. 773 Downloaded by guest on September 23, 2021 1-74. BIOCHEMISTRY: BUEDING ET AL. PROC. N. A. S. ATP was added to the experimental samples before, and to the control samples immediately after, incubation. Proteins and phosphate esters were precipitated with barium hydroxide and zinc sulfate,'0 and the concentration of the nonphos- phorylated hexose was determined in the filtrate."' 12 Hexose utilization was calculated from the difference between the free hexose concentration (reaction mixture incubated without ATP) and the experimental sample. Glucosamine-6- phosphate was prepared according to Brown.9 Glucosamine kinase was purified as follows: adult male schistosomes were homogenized in 0.01 M glycylglycine buffer (pH 7.5; 1 ml. of buffer was used per 140 worms), and the protein concentration of the homogenate was adjusted to 5.0 mg/ml by dilution with the buffer. 0.04 ml. of alumina gel CQ (23 mg. of dry weight per milliliter of gel) were added per milli- liter of homogenate. The mixture was stirred and then centrifuged. Addition of 0.04 ml. of the same gel per milliliter of supernatant and subsequent elution of the residue with glycylglycine buffer (0.06 M; pH 7.5) yielded a fraction containing glucokinase activity. All operations were carried out at temperatures ranging between 00 and 4° C. Incubation of schistosome homogenates with glucosamine, ATP, and MgCl2 resulted in the disappearance of the free amino sugar. This suggested that the TABLE 1 GLUCOSAMINE KINASE AND GLUCOKINASE ACTIVITIES OF A HOMOGENATE OF Schistosoma mansoni GLUCOSAMINE KINASE GLUCOKINA8E Per Cent Per Cent ADDITION Activity* Inhib. Activity* Inhib. None 0.21 .. 0.65 0.004 M glucosamine-6-phos- phate 0.12 43 0.28 57 0.0016 M glucosamine-6-phos- phate 0.18 14 0.54 17 0.01 M N-acetylglucosamine 0 05 76 0.003 M N-acetylglucosamine 0.13 38 * Micromoles of free hexo8e phosphorylated per milligram of protein. enzyme preparation of the worms catalyzed the phosphorylation of glucosamine. Evidence for the formation of a phosphate ester of glucosamine under these conditions was obtained by the isolation of a water-soluble, alcohol-insoluble barium salt from the deproteinized reaction mixture. After the removal of the barium, analysis of this material for acid-stable organic phosphate and for glucosamine"2 as well as fractionation by ion-exchange chromatography" revealed that the com- pound had characteristics identical with those of glucosamine-6-phosphate.9 13 These data indicated that the compound was not identical with glucosamine-l- phosphate. Because of the limited amount of available organisms, it was not possible to obtain this compound in sufficient quantities to determine whether phos- phorylation had occurred in positions 6, 3, 4, or 5. Glucose did not inhibit the phosphorylation of glucosamine, nor did glucosamine affect the activity of glucokinase. Therefore, neither of these two hexoses inter- fered with the phosphorylation of the other by schistosome homogenates. It has been reported that N-acetylglucosamine inhibits the phosphorylation of glucosamine by brain hexokinase.14 Similarly, N-acetylglucosamine reduced the activity of the worm enzyme which catalyzes the phosphorylation of glucosamine (Table 1). Crane and Sols have demonstrated that glucose-6-phosphate inhibits the activity Downloaded by guest on September 23, 2021 VOL. 40Y 19D54 BIOCHEMISTRY: BUEDING ET AL. 775 of brain hexokinase.7' 15 While this ester did not affect the phosphorylation of fruc- tose, it did inhibit the phosphorylation of glucose and of mannose by homogenates and by extracts of schistosomes.6 Glucosamine-6-phosphate inhibited glucosamine kinase and glucokinase activity of schistosomes (Table 1); however, higher concen- trations were required to produce this effect than in the case of glucose-6-phosphate. On fractionation of homogenates of male schistosomes by the use of alumina gel C,, an enzyme extract was obtained which contains glucosamine kinase, free of glucokinase activity (Table 2). It has been found previously that purified gluco- kinase, fructokinase, and mannokinase of schistosomes do not react with glucos- amine.3 Therefore, in Schistosoma mansoni phosphorylations of glucosamine and of glucose are catalyzed by two different enzymes. TABLE 2 GLUCOSAMINE KINASE ACTIVITY OF A FRACTION OF A MALE SCHISTOSOME HOMOGENATE PURIFIED BY USE OF ALUMINA CTy Experiment Glucosamine Kinase Glucokinase No. Activity* Activity* 1 7.6 0 2 5.4 0 3 9.2 0 * Micromoles of free hexose phosphorylated per milligram of protein. The occurrence in the worms of a glucosamine kinase whose activity is not affected by glucose raised the question whether a phosphate ester of glucosamine or a metabolic product thereof interferes with chemical reactions essential for the survival of the worms. Such a possibility was suggested by the inhibitory effect of glucosamine-6-phosphate on the glucokinase of the parasite as well as by the fact that glucosamine reduced the rate of glyoolysis of intact schistosomes.3 This problem was studied by determining the effect of glucosamine on the parasites in vitro and in vivo. In a chemically defined medium the schistosomes survive for a period of 5-6 days. 16 Addition of glucosamine to this medium resulted in a signifi- cant reduction of their survival (Table 3). The action of glucosamine was not affected by the concentration of glucose in the medium. Accordingly, there was no evidence for a competition between glucose and glucosamine. Reduction of the survival of the parasite by glucosamine was observed also when horse serum was used as the medium (Table 3). TABLE 3 EFFECT OF GLUCOSAMINE ON SURVIVAL OF Schistosoma manmoni IN VITRO Glucosamine Average Survival Reduction of Survival Medium (Mg/Ml) (Days) (Per Cent) 6.2 Synthetic{ 3. 1.1 82 ]1.2 2.3 63 t0.4 3.9 37 23.0 Serum 3 0 6.2 73 1.2 9.8 58 O0.4 15.9 31 Oral administration of glucosamine to mice infected with Schistosoma mansoni resulted in a change in the distribution of the worms in the host. The adult schistosomes are located in the mesenteric veins, in the portal vein, and in the liver Downloaded by guest on September 23, 2021 776 BIOCHEMISTRY: BUEDING ET AL. PROC. N. A. S. sinuses. When the worms are damaged by chemotherapeutic agents, such as organic antimonials, they lose their attachment in the mesenteric veins and migrate toward the liver. Such an effect was observed after oral or intraperitoneal administration of glucosamine; under these conditions a significant reduction in the number of worms in the mesenteric veins occurred which was associated with a corresponding increase of worms in the liver (Table 4). The differences in the distribution of the TABLE 4 EFFECT OF ORAL ADMINISTRATION OF GLUCOSAMINE TO MICE INFECTED WITH Schistosoma mansoni ON DISTRIBUTION OF WORMS IN PORTALHEPATO-VENOUS SYSTEM OF HOST* TOTAL No. .-PERCENTAGE OF WORMS IN-- EXPERIMENT No. OF OF WORMS Mesenteric Portal No. GROUP MICE (Av.) Veins Vein Liver fControl 7 28.7 54 40 6 1 \Experimental 13 28.7 30 41 29 2 fControl 11 25.9 47 41 12 Experimental 10 24.7 32 38 30 * Glucosamine was administered twice daily (10 per cent solution; pH 6.0) at a single dose of 50 mg.
Recommended publications
  • A Little Sugar Goes a Long Way: the Cell Biology of O-Glcnac
    Published March 30, 2015 JCB: Review A little sugar goes a long way: The cell biology of O-GlcNAc Michelle R. Bond and John A. Hanover Unlike the complex glycans decorating the cell surface, the to nucleocytoplasmic kinases and phosphatases. In fact, there are O-linked -N-acetyl glucosamine (O-GlcNAc) modifica- many parallels between phosphorylation and O-GlcNAcylation: O-GlcNAc is added to Ser and Thr residues; the modification tion is a simple intracellular Ser/Thr-linked monosaccha- rapidly cycles on and off modified proteins at a rate faster than ride that is important for disease-relevant signaling and protein turnover; and like kinases and phosphatases, OGT and enzyme regulation. O-GlcNAcylation requires uridine OGA are phosphorylated (Fig. 1 B; Butkinaree et al., 2010; diphosphate–GlcNAc, a precursor responsive to nutrient Hanover et al., 2010). Many target proteins are modified by both status and other environmental cues. Alternative splicing O-GlcNAc and phosphate at exposed regions, suggesting the of the genes encoding the O-GlcNAc cycling enzymes presence of shared or coexisting recognition motifs. However, although the sites of protein phosphorylation can often be identified Downloaded from O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) by primary sequence alone, O-GlcNAcylation is not associated yields isoforms targeted to discrete sites in the nucleus, cy- with a clear consensus motif. toplasm, and mitochondria. OGT and OGA also partner OGT uses UDP-GlcNAc, a nucleotide sugar derived from with cellular effectors and act in tandem with other post- the nutrient-dependent hexosamine biosynthetic pathway (HBP), translational modifications. The enzymes of O-GlcNAc to catalyze O-GlcNAc addition (Fig.
    [Show full text]
  • SUPPY Liglucosexlmtdh
    US 20100314248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0314248 A1 Worden et al. (43) Pub. Date: Dec. 16, 2010 (54) RENEWABLE BOELECTRONIC INTERFACE Publication Classification FOR ELECTROBOCATALYTC REACTOR (51) Int. Cl. (76) Inventors: Robert M. Worden, Holt, MI (US); C25B II/06 (2006.01) Brian L. Hassler, Lake Orion, MI C25B II/2 (2006.01) (US); Lawrence T. Drzal, Okemos, GOIN 27/327 (2006.01) MI (US); Ilsoon Lee, Okemo s, MI BSD L/04 (2006.01) (US) C25B 9/00 (2006.01) (52) U.S. Cl. ............... 204/403.14; 204/290.11; 204/400; Correspondence Address: 204/290.07; 427/458; 204/252: 977/734; PRICE HENEVELD COOPER DEWITT & LIT 977/742 TON, LLP 695 KENMOOR, S.E., PO BOX 2567 (57) ABSTRACT GRAND RAPIDS, MI 495.01 (US) An inexpensive, easily renewable bioelectronic device useful for bioreactors, biosensors, and biofuel cells includes an elec (21) Appl. No.: 12/766,169 trically conductive carbon electrode and a bioelectronic inter face bonded to a surface of the electrically conductive carbon (22) Filed: Apr. 23, 2010 electrode, wherein the bioelectronic interface includes cata lytically active material that is electrostatically bound directly Related U.S. Application Data or indirectly to the electrically conductive carbon electrode to (60) Provisional application No. 61/172,337, filed on Apr. facilitate easy removal upon a change in pH, thereby allowing 24, 2009. easy regeneration of the bioelectronic interface. 7\ POWER 1 - SUPPY|- LIGLUCOSEXLMtDH?till pi 6.0 - esses&aaaas-exx-xx-xx-xx-xxxxixax-e- Patent Application Publication Dec. 16, 2010 Sheet 1 of 18 US 2010/0314248 A1 Potential (nV) Patent Application Publication Dec.
    [Show full text]
  • N-Acetyl-D-Glucosamine Kinase Is a Component of Nuclear Speckles and Paraspeckles
    Mol. Cells 2015; 38(5): - http://dx.doi.org/10.14348/molcells.2015.2242 Molecules and Cells http://molcells.org Established in 1990 N-Acetyl-D-Glucosamine Kinase is a Component of Nuclear Speckles and Paraspeckles Syeda Ridita Sharif1,4, HyunSook Lee2,4, Md. Ariful Islam1, Dae-Hyun Seog3, and Il Soo Moon1,2,* Protein O-GlcNAcylation, dictated by cellular UDP-N- conformational change in which the two domains close around acetylglucosamine (UDP-GlcNAc) levels, plays a crucial role the nucleotide (Hurley, 1996). N-acetylglucosamine kinase in posttranslational modifications. The enzyme GlcNAc (GlcNAc kinase or NAGK; E.C. 2.7.1.59), an enzyme of the sug- kinase (NAGK, E.C. 2.7.1.59) catalyzes the formation of ar-kinase/Hsp70/actin super family (Berger et al., 2002), was first GlcNAc-6-phosphate, which is a major substrate for the identified in 1970 (Datta, 1970). NAGK is a prominent enzyme in biosynthesis of UDP-GlcNAc. Recent studies have revealed amino sugar metabolism where it catalyzes the conversion of the expression of NAGK in different types of cells especially GlcNAc to GlcNAc-6-phosphate. This metabolic pathway even- in neuronal dendrites. Here, by immunocytochemistry (ICC) tually yields to UDP-GlcNAc, which is utilized in the synthesis of and immunonucleochemistry (INC) of cultured rat hippo- O-/N-glycans and sialic acid. UDP-GlcNAc is also a substrate for campal neurons, HEK293T and GT1-7 cells we have showed O-GlcNAc transferase, which modifies cytosolic and nuclear that NAGK immuno-reactive punctae being present in the proteins at serine or threonine residues by adding a single nucleoplasm colocalized with small nuclear ribonucleoprotein- GlcNAc.
    [Show full text]
  • Conserved Phosphoryl Transfer Mechanisms Within Kinase Families
    Kenyon et al. BMC Research Notes 2012, 5:131 http://www.biomedcentral.com/1756-0500/5/131 RESEARCHARTICLE Open Access Conserved phosphoryl transfer mechanisms within kinase families and the role of the C8 proton of ATP in the activation of phosphoryl transfer Colin P Kenyon*, Robyn L Roth, Chris W van der Westhuyzen and Christopher J Parkinson Abstract Background: The kinome is made up of a large number of functionally diverse enzymes, with the classification indicating very little about the extent of the conserved kinetic mechanisms associated with phosphoryl transfer. It has been demonstrated that C8-H of ATP plays a critical role in the activity of a range of kinase and synthetase enzymes. Results: A number of conserved mechanisms within the prescribed kinase fold families have been identified directly utilizing the C8-H of ATP in the initiation of phosphoryl transfer. These mechanisms are based on structurally conserved amino acid residues that are within hydrogen bonding distance of a co-crystallized nucleotide. On the basis of these conserved mechanisms, the role of the nucleotide C8-H in initiating the formation of a pentavalent intermediate between the g-phosphate of the ATP and the substrate nucleophile is defined. All reactions can be clustered into two mechanisms by which the C8-H is induced to be labile via the coordination of a backbone carbonyl to C6-NH2 of the adenyl moiety, namely a “push” mechanism, and a “pull” mechanism, based on the protonation of N7. Associated with the “push” mechanism and “pull” mechanisms are a series of proton transfer cascades, initiated from C8-H, via the tri-phosphate backbone, culminating in the formation of the pentavalent transition state between the g-phosphate of the ATP and the substrate nucleophile.
    [Show full text]
  • THE DEVELOPMENT of CHEMICAL METHODS to DISCOVER KINASE SUBSTRATES and MAP CELL SIGNALING with GAMMA-MODIFIED ATP ANALOG-DEPENDENT KINASE-CATALYZED PHOSPHORYLATION By
    Wayne State University Wayne State University Dissertations 1-1-2017 The evelopmeD nt Of Chemical Methods To Discover Kinase Substrates And Map Cell Signaling With Gamma-Modified Atp Analog- Dependent Kinase-Catalyzed Phosphorylation Dissanayaka Mudiyanselage Maheeka Madhubashini Embogama Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Analytical Chemistry Commons, and the Biochemistry Commons Recommended Citation Embogama, Dissanayaka Mudiyanselage Maheeka Madhubashini, "The eD velopment Of Chemical Methods To Discover Kinase Substrates And Map Cell Signaling With Gamma-Modified Atp Analog-Dependent Kinase-Catalyzed Phosphorylation" (2017). Wayne State University Dissertations. 1698. https://digitalcommons.wayne.edu/oa_dissertations/1698 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. THE DEVELOPMENT OF CHEMICAL METHODS TO DISCOVER KINASE SUBSTRATES AND MAP CELL SIGNALING WITH GAMMA-MODIFIED ATP ANALOG-DEPENDENT KINASE-CATALYZED PHOSPHORYLATION by DISSANAYAKA M. MAHEEKA M. EMBOGAMA DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2017 MAJOR: CHEMISTRY (Biochemistry) Approved By: Advisor Date DEDICATION To my beloved mother, father, husband, daughter and sister. ii ACKNOWLEGEMENTS Many people have helped me during the past five years of earning my PhD. I would like to take this opportunity to convey my gratitude to them. First and foremost, I would like to thank my research supervisor Dr. Mary Kay Pflum for being the greatest mentor that I have met so far.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch Et Al
    US 20100158968A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch et al. (43) Pub. Date: Jun. 24, 2010 (54) CELL-PERMEANT PEPTIDE-BASED Publication Classification INHIBITOR OF KINASES (51) Int. Cl. (76) Inventors: Alyssa Panitch, West Lafayette, IN st e8 CR (US); Brandon Seal, West ( .01) Lafayette, IN (US) A638/10 (2006.01) s A638/16 (2006.01) Correspondence Address: A6IP 43/00 (2006.01) GREENBERG TRAURIG, LLP (52) U.S. Cl. ................ 424/422:514/15: 514/13: 514/14 200 PARKAVE., P.O. BOX 677 FLORHAMPARK, NJ 07932 (US) (57) ABSTRACT The described invention provides kinase inhibiting composi (21) Appl. No.: 12/634,476 tions containing a therapeutic amount of a therapeutic inhibi (22) Filed: Dec. 9, 2009 torpeptide that inhibits at least one kinase enzyme, methods e 19 for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods Related U.S. Application Data for treating an inflammatory disorder whose pathophysiology (60) Provisional application No. 61/121,396, filed on Dec. comprises inflammatory cytokine expression using the kinase 10, 2008. inhibiting compositions. 20 { ki> | 0: & c s - --- 33- x: SE PEPELE, ics 1.-- E- X K. AAA 22.9 --- KKK. Y.A., 3.2; C. -r { AAEASA. A. E. i : A X AAAAAAA; ; ; ; :-n. 4:-: is SEEKESAN.ARESA, 3523 -- -- Yili.A.R.AKA: 5,342 3. {{RCE: Rix i: Patent Application Publication US 2010/0158968A1 & ******** NO s ***** · Patent Application Publication Jun. 24, 2010 Sheet 2 of 11 US 2010/0158968A1 it, O Peptide: Cso: g E 100 WRRKAWRRKANRO, GWAA.
    [Show full text]
  • High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
    Supplementary Information High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype Håkon Reikvam 1,2,*, Elise Aasebø 1, Annette K. Brenner 2, Sushma Bartaula-Brevik 1, Ida Sofie Grønningsæter 2, Rakel Brendsdal Forthun 2, Randi Hovland 3,4 and Øystein Bruserud 1,2 1 Department of Clinical Science, University of Bergen, 5020, Bergen, Norway 2 Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway 3 Department of Medical Genetics, Haukeland University Hospital, 5021, Bergen, Norway 4 Institute of Biomedicine, University of Bergen, 5020, Bergen, Norway * Correspondence: [email protected]; Tel.: +55-97-50-00 J. Clin. Med. 2019, 8, x 2 of 36 Figure S1. Mutational studies in a cohort of 71 AML patients. The figure shows the number of patients with the various mutations (upper), the number of mutations in for each patient (middle) and the number of main classes with mutation(s) in each patient (lower). 2 J. Clin. Med. 2019, 8, x; doi: www.mdpi.com/journal/jcm J. Clin. Med. 2019, 8, x 3 of 36 Figure S2. The immunophenotype of primary human AML cells derived from 62 unselected patients. The expression of the eight differentiation markers CD13, CD14, CD15, CD33, CD34, CD45, CD117 and HLA-DR was investigated for 62 of the 71 patients included in our present study. We performed an unsupervised hierarchical cluster analysis and identified four patient main clusters/patient subsets. The mutational profile for each f the 62 patients is also given (middle), no individual mutation of main class of mutations showed any significant association with any of the for differentiation marker clusters (middle).
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Supplementary Information
    Supplementary information (a) (b) Figure S1. Resistant (a) and sensitive (b) gene scores plotted against subsystems involved in cell regulation. The small circles represent the individual hits and the large circles represent the mean of each subsystem. Each individual score signifies the mean of 12 trials – three biological and four technical. The p-value was calculated as a two-tailed t-test and significance was determined using the Benjamini-Hochberg procedure; false discovery rate was selected to be 0.1. Plots constructed using Pathway Tools, Omics Dashboard. Figure S2. Connectivity map displaying the predicted functional associations between the silver-resistant gene hits; disconnected gene hits not shown. The thicknesses of the lines indicate the degree of confidence prediction for the given interaction, based on fusion, co-occurrence, experimental and co-expression data. Figure produced using STRING (version 10.5) and a medium confidence score (approximate probability) of 0.4. Figure S3. Connectivity map displaying the predicted functional associations between the silver-sensitive gene hits; disconnected gene hits not shown. The thicknesses of the lines indicate the degree of confidence prediction for the given interaction, based on fusion, co-occurrence, experimental and co-expression data. Figure produced using STRING (version 10.5) and a medium confidence score (approximate probability) of 0.4. Figure S4. Metabolic overview of the pathways in Escherichia coli. The pathways involved in silver-resistance are coloured according to respective normalized score. Each individual score represents the mean of 12 trials – three biological and four technical. Amino acid – upward pointing triangle, carbohydrate – square, proteins – diamond, purines – vertical ellipse, cofactor – downward pointing triangle, tRNA – tee, and other – circle.
    [Show full text]
  • N-Acetyl-D-Glucosamine Kinase Interacts with Nudc and Lis1 in Dynein Motor Complex and Promotes Cell Migration
    International Journal of Molecular Sciences Article N-Acetyl-D-Glucosamine Kinase Interacts with NudC and Lis1 in Dynein Motor Complex and Promotes Cell Migration Md. Ariful Islam 1,†, Ho Jin Choi 1, Raju Dash 1 , Syeda Ridita Sharif 1,‡, Diyah Fatimah Oktaviani 1 , Dae-Hyun Seog 2 and Il Soo Moon 1,3,* 1 Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Korea; [email protected] (M.A.I.); [email protected] (H.J.C.); [email protected] (R.D.); [email protected] (S.R.S.); [email protected] (D.F.O.) 2 Department of Biochemistry, Dementia and Neurodegenerative Disease Research Center, Inje University College of Medicine, Busan 47392, Korea; [email protected] 3 Dongguk Medical Institute, Dongguk University College of Medicine, Gyeongju 38066, Korea * Correspondence: [email protected]; Tel.: +82-54-770-2414; Fax: +82-54-770-2447 † Current address: Departments of Biological Sciences & Brain and Cognitive Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea. ‡ Current address: Department of Pharmacy, University of Science and Technology Chittagong, Chittagong 4202, Bangladesh. Abstract: Recently, we showed that N-acetylglucosamine kinase (NAGK), an enzyme of amino sugar metabolism, interacts with dynein light chain roadblock type 1 (DYNLRB1) and promotes the functions of dynein motor. Here, we report that NAGK interacts with nuclear distribution protein C (NudC) and lissencephaly 1 (Lis1) in the dynein complex. Yeast two-hybrid assays, pull-down assays, immunocy- tochemistry, and proximity ligation assays revealed NAGK–NudC–Lis1–dynein complexes around nuclei, at the leading poles of migrating HEK293T cells, and at the tips of migratory processes of cultured rat neuroblast cells.
    [Show full text]
  • (12) STANDARD PATENT (11) Application No. AU 2015215937 B2 (19) AUSTRALIAN PATENT OFFICE
    (12) STANDARD PATENT (11) Application No. AU 2015215937 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Metabolically engineered organisms for the production of added value bio-products (51) International Patent Classification(s) C12N 15/52 (2006.01) C12P 19/26 (2006.01) C12P 19/18 (2006.01) C12P 19/30 (2006.01) (21) Application No: 2015215937 (22) Date of Filing: 2015.08.21 (43) Publication Date: 2015.09.10 (43) Publication Journal Date: 2015.09.10 (44) Accepted Journal Date: 2017.03.16 (62) Divisional of: 2011278315 (71) Applicant(s) Universiteit Gent (72) Inventor(s) MAERTENS, Jo;BEAUPREZ, Joeri;DE MEY, Marjan (74) Agent / Attorney Griffith Hack, GPO Box 3125, Brisbane, QLD, 4001, AU (56) Related Art Trinchera, M. et al., 'Dictyostelium cytosolic fucosyltransferase synthesizes H type 1 trisaccharide in vitro', FEBS Letters, 1996, Vol. 395, pages 68-72 GenBank accession no. AF279134, 6 May 2002 van der Wel, H. et al., 'A bifunctional diglycosyltransferase forms the Fuc#1,2Gal#1,3-disaccharide on Skpl in the cytoplasm of Dictyostelium', The Journal of Biological Chemistry, 2002, Vol. 277, No. 48, pages 46527-46534 WO 2010/070104 Al Abstract The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.
    [Show full text]
  • Enzymatic Post‐Translational Modifications Linking
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kanazawa University Repository for Academic Resources Enzymatic and non-enzymatic post-translational modifications linking diabetes and heart disease 著者 Yamamoto Yasuhiko, Yamamoto Hiroshi journal or Journal of Diabetes Investigation publication title volume 6 number 1 page range 16-17 year 2015-01-01 URL http://hdl.handle.net/2297/45821 doi: 10.1111/jdi.12248 COMMENTARY Enzymatic and non-enzymatic post-translational modifications linking diabetes and heart disease Diabetes-related morbidity and mortality has received considerable attention as a however, its flux is upregulated in dia- is evident in the increased prevalence of key factor in diabetic cardiac pathology2,3. betic cardiomyocytes4. The rate-limiting cardiovascular diseases and the high-risk In contrast to non-enzymatic glycation enzyme glutamine, fructose-6-phosphate of heart failure. Diabetic cardiomyopathy reactions, O-GlcNAc glycosylation is a aminotransferase (GFAT), converts fruc- is a well-known complication of diabetes, reversible and labile post-translational tose-6-phosphate to glucosamine-6-phos- and is defined as a ventricular dysfunc- modification. phate, which is then converted into tion independent of coronary heart After entering a cell, glucose is phos- UDP-GlcNAc and transferred onto target diseases and hypertension. The Framing- phorylated to glucose-6-phosphate (Fig- proteins by O-GlcNAc transferase ham study firmly established an epidemi- ure 1). It is further metabolized during (OGT). The enzyme, O-GlcNAcase, cata- ological link between diabetes and heart glycolysis to fructose-6-phosphate, which lyzes the removal of the O-GlcNAc failure1.Diabetescausesmetabolicdistur- leads to accessory pathways of glucose adduct from O-GlcNAcylated proteins bances, cardiac fibrosis, endothelial and metabolism; one such pathway is the (Figure 1)2.
    [Show full text]